Posted on August 15, 2026 by Sunny Singh
You’ve seen this movie before. Your clinical champion is sold. The surgeon has used the device in a trial, loves the outcomes, and is ready to go to bat for you internally. Your sales rep is writing the deal into the forecast. Everyone on your team is treating it like a closed contract.
Six months later, nothing has moved
The deal hasn’t died. Nobody told you no. The surgeon still wants it. But the hospital hasn’t bought anything. And no one on your team can explain exactly why.
This is one of the most expensive and least understood patterns in medical device commercialization. It drains pipeline, burns sales cycles, and quietly erodes the confidence of investors and board members who are watching conversion rates stall for reasons that never show up in your CRM.
The root issue is structural, and it applies to almost every medtech company selling medical devices to hospitals today: clinician enthusiasm is necessary but wildly insufficient to close an institutional deal. And the gap between those two things is where most commercial strategies fall apart.
When a physician champion advocates for your product internally, they are making a clinical case. They’re talking about patient outcomes, procedural efficiency, technical superiority. This is the language they know and the lens through which they evaluate new technology.
The problem is that the hospital purchasing process for medical devices doesn’t run through a clinical lens alone. The institution has an entirely different set of concerns, and in most health systems today, those concerns carry more weight than physician preference.
Physician preference items (PPIs) are products where the individual clinician’s choice historically drove the purchasing decision. According to Definitive Healthcare, PPIs account for 40% to 60% of total hospital supply costs. That number alone explains why health systems have built formal governance structures around purchasing. When a single category of spending represents that much of a hospital’s supply budget, the institution cannot afford to let individual clinician enthusiasm drive procurement.
This shift accelerated over the past decade with the widespread adoption of value analysis committees. A value analysis committee (VAC) is a multi-disciplinary hospital body that evaluates all new product purchases based on clinical evidence, cost-effectiveness, operational impact, and strategic fit. Symplr reports that VACs were created in direct response to cost-cutting pressures, as hospitals realized that significant excess expenditure was occurring in their supply chain processes. A study published in Value in Health found that by 2014, 100% of hospitals surveyed reported using a VAC for all new products being considered.
If your medical device hospital sales strategy still assumes that winning the clinician wins the deal, you are operating with a model that stopped working years ago.
The approach to selling medical devices to hospitals that works in 2026 requires understanding who sits at the table and what each person cares about. This is where most medtech companies lose deals they thought they had won.
A typical hospital buying process involves some combination of the following stakeholders: the physician champion, the department head, supply chain leadership, the value analysis committee, finance, sometimes IT, and sometimes risk management or legal. Each group evaluates your product through a completely different set of criteria.
The physician wants to know if it works better. Supply chain wants to know if it integrates with existing vendor contracts and GPO agreements. The hospital CFO wants to understand total cost of ownership, reimbursement impact, and whether this is a budgeted or unbudgeted expense. The value analysis committee wants clinical evidence, cost comparisons against existing alternatives, implementation plans, and proof that adoption won’t disrupt operations.
A systematic review published in BMJ Open found that the two most prominent elements across hospital purchasing processes were the roles of various stakeholders and the approaches to balancing technical, financial, and clinical requirements. The research also found that clinical evidence and cost-effectiveness consistently ranked as more important than personal preference, regardless of the stakeholder’s role.
This matters because it means even the people on the committee who are clinicians are evaluating your device through a value-based lens, not just a clinical preference lens. Your surgeon champion’s enthusiasm gets you to the table. It does not get you through it.
One of the most frustrating dynamics for medtech sales teams is the expanding hospital deal cycle for medical devices. What might have closed in 60 to 90 days a decade ago now routinely takes six months, nine months, sometimes over a year.
This isn’t because hospitals are indecisive. It’s because the buying process has become structurally more complex.
NAMSA’s 2025 Hospital Purchasing Behavior report, based on surveys of 100 procurement decision-makers across U.S. and European hospitals, found that procurement processes are slowing down due to regulatory complexity, increased stakeholder involvement, and growing demands for robust clinical evidence. One Chief of Operations surveyed in the report said they are taking extra time to assess risks and ensure they are making the best possible choice, given rapid shifts in healthcare policies, reimbursement models, and emerging technologies.
At the same time, hospitals are operating on historically thin margins. Strata Decision Technology’s data shows that median health system operating margins hovered near 1% throughout 2025, with the year-end figure settling at 1.3% in December before declining again. The American Hospital Association reports that Medicare reimbursed hospitals at just 83 cents on the dollar in 2024, resulting in over $100 billion in underpayments. When your operating margin is that thin, every purchasing decision receives additional scrutiny. The hospital CFO’s office is not rubber-stamping anything, regardless of how enthusiastic the surgical team is.
This is the financial reality your product is entering. And most medtech companies are not building their commercial materials or sales processes around it.
Here is where the disconnect between clinician enthusiasm and hospital adoption becomes most visible. Your clinical champion is convinced because they’ve used the device and seen the results firsthand. That personal experience is powerful for them. It is almost meaningless to a value analysis committee.
What the VAC needs is structured evidence: peer-reviewed clinical data, health economic analyses, comparative cost studies against the current standard of care, implementation timelines, training requirements, EHR compatibility documentation, and case studies from comparable facilities that have already adopted the technology. ECRI Institute’s David Berkowitz has noted that the biggest mistake device companies make is focusing on features and benefits rather than evidence and comparative effectiveness.
Most medical device companies in the $5M to $50M range do not have this package ready. They have clinical data (sometimes), a few case studies (usually informal), and a pricing sheet. That is not a value analysis committee submission. That is a brochure.
The companies that close hospital deals consistently have built what I’d call an institutional evidence portfolio. This is a complete set of materials designed for each stakeholder in the buying process, not just the clinician. It includes the clinical narrative, yes, but also the economic value story for finance, the operational integration plan for supply chain, the reimbursement analysis for the billing team, and the risk assessment for compliance.
Building this portfolio is not a sales enablement project. It’s a commercial strategy decision that should be made long before your first rep walks into a hospital.
None of this means the clinician champion is unimportant. They are essential. Without physician interest and advocacy, most devices never even get on the VAC’s agenda. In many facilities, the committee won’t consider a product unless a physician has formally requested it and demonstrated that it has been budgeted or that there is an established clinical need.
But here’s what the champion cannot do: they cannot answer the hospital CFO’s question about total cost of ownership. They cannot address supply chain’s concern about vendor consolidation. They cannot provide the comparative cost data the VAC requires. They cannot present the reimbursement analysis that the billing department needs. And in many cases, the physician is not even permitted to be in the room when the committee deliberates.
NICO Corporation CEO Jim Pearson described this dynamic clearly. He noted that typically, there is limited or no vendor-to-VAC communication. Discussions take place through the physician, who must complete questions on a template or form. The vendor is generally not permitted to attend meetings or communicate directly with the committee. That means the physician champion is essentially presenting your business case on your behalf, with whatever materials you gave them.
If those materials only cover clinical performance, that’s all they can present. And that’s not enough.
The best-performing medtech companies treat the physician champion as one part of a broader institutional sales strategy. They equip the champion with the right materials for their role (the clinical case), while simultaneously building relationships and delivering evidence to supply chain, finance, and the VAC through parallel channels.
If your pipeline is full of deals where the clinician is sold but the institution hasn’t moved, the problem is almost certainly strategic, not tactical. You don’t need more reps making more calls. You need a fundamentally different approach to how you engage with the hospital as an institution.
That starts with mapping the full buying committee at each target account before you ever engage. Who sits on the VAC? What evidence do they require? What’s the submission process? What’s the hospital budget cycle? Which GPO contracts are in play? What are the facility’s stated strategic priorities for this fiscal year?
It continues with building your institutional evidence portfolio to address each stakeholder’s specific concerns. Clinical evidence for the clinician. Economic value analysis for finance. Operational integration plans for supply chain. Reimbursement pathway documentation for the billing team.
And it requires aligning your sales process to the hospital’s buying process, not the other way around. Most medtech companies run a sales motion built around the physician relationship. The hospital runs a procurement process built around committee governance, budget cycles, and evidence review. When those two processes aren’t aligned, deals stall. Every time.
I wrote extensively about how to build this kind of multi-stakeholder hospital adoption framework in [The 2026 Hospital Adoption Playbook for Medical Device Companies](https://sunnyfractionalcmo.gumroad.com/l/thecompletehospitaladoptionplaybookformedicaldevices).
It covers the full institutional buying process, from VAC navigation to stakeholder mapping to building the economic evidence package that gets deals through committee. If your team is losing time and revenue to deals that stall after the clinician says yes, the playbook was written for exactly that problem. You can download it and start applying the frameworks immediately.
Everything I’ve described is going to intensify in the coming years. Hospital supply costs have been rising at roughly 8% annually since 2020, according to Definitive Healthcare, with U.S. hospitals reporting over $60 billion in combined medical and surgical supply costs in 2024. National hospital spending accounted for 40% of the growth in total health expenditures between 2022 and 2024, per KFF analysis of CMS data. Supply expenses jumped 12% year-over-year in 2025, and drug expenses rose at a similar rate, according to Strata Decision Technology.
In that environment, hospitals are going to demand more evidence, involve more stakeholders, and take longer to make purchasing decisions. The NAMSA data supports this. The Strata Decision data supports this. The structural economics of hospital operations support this.
Medical device companies that continue to treat clinician enthusiasm as a proxy for deal readiness are going to keep watching their pipeline age and their conversion rates decline. The companies that build a true medical device hospital sales strategy, one that treats the institution as the buyer and the physician as one critical voice among several, will close faster and more consistently.
The clinical champion opens the door. But the door leads to a conference room full of people your sales team has never met, asking questions your marketing team has never prepared for. Solving that gap is the single highest-leverage commercial investment most medtech companies can make right now.
Hospital purchasing has shifted from physician-driven procurement to committee-based governance through value analysis committees. This change was driven by cost pressures, as physician preference items represent 40% to 60% of hospital supply costs according to Definitive Healthcare. A study published in Value in Health found that 100% of hospitals surveyed now use a VAC for all new products being considered. Hospitals now require formal evidence review, cost-benefit analysis, and multi-stakeholder approval before purchasing new medical devices, regardless of individual physician preference.
A value analysis committee (VAC) is a multi-disciplinary hospital body that evaluates all new product purchases based on clinical evidence, cost-effectiveness, operational impact, and strategic fit. VACs typically include physicians, nurses, supply chain specialists, finance representatives, and administrators. For medical device companies, the VAC is the actual decision-maker in the purchasing process, and vendors frequently have limited or no direct communication with the committee during deliberations. Companies must prepare comprehensive evidence packages addressing clinical, economic, and operational criteria to succeed in VAC evaluations.
Hospital purchasing decisions for medical devices involve multiple stakeholders including the physician champion, department head, supply chain leadership, the value analysis committee, finance, and sometimes IT and legal. A systematic review published in BMJ Open found that clinical evidence and cost-effectiveness consistently ranked as more important than personal preference, regardless of the stakeholder’s role. The process typically requires a formal submission to the VAC with peer-reviewed clinical data, comparative cost analyses, implementation plans, and reimbursement documentation.
Hospital procurement timelines now routinely take six to twelve months or longer for significant purchases. NAMSA’s 2025 Hospital Purchasing Behavior report, based on surveys of 100 procurement decision-makers, found that procurement processes are slowing due to regulatory complexity, increased stakeholder involvement, and demands for robust clinical evidence. Hospital budget cycles, GPO contract alignment, and VAC meeting schedules further extend these timelines, particularly in an environment where median health system operating margins have held near 1%.
Deals stall because clinician enthusiasm addresses only the clinical dimension of a multi-stakeholder purchasing decision. The hospital buying process involves supply chain, finance, the value analysis committee, and sometimes IT and legal, each evaluating the device through different criteria. When medical device companies only equip their champion with clinical evidence, the institutional stakeholders’ questions about total cost of ownership, operational integration, reimbursement risk, and vendor consolidation go unanswered, causing the deal to stall indefinitely.
Hospitals require a comprehensive evidence package that goes far beyond clinical data. Value analysis committees evaluate peer-reviewed clinical studies, health economic analyses, comparative cost data against existing alternatives, implementation and training plans, EHR and IT compatibility documentation, reimbursement pathway analysis, and case studies from comparable facilities. ECRI Institute has noted that the biggest mistake device companies make is focusing on features and benefits rather than evidence and comparative effectiveness. Price was identified as the most important VAC consideration, though patient experience and value-based purchasing elements are also evaluated.
Hospital CFOs evaluate medical device purchases through a financial lens that includes total cost of ownership (not just acquisition price), reimbursement impact, budget cycle alignment, and projected volume-based cost modeling. With median health system operating margins near 1% according to Strata Decision Technology and Medicare reimbursing at just 83 cents on the dollar per the AHA, CFOs are applying heightened scrutiny to every purchasing decision. Devices that can demonstrate measurable cost savings, reduced length of stay, or improved reimbursement rates receive significantly more favorable evaluation.
Companies can improve hospital deal conversion by mapping the full buying committee at each target account, building an institutional evidence portfolio that addresses each stakeholder’s concerns (clinical, economic, operational, and compliance), aligning the sales process to the hospital’s procurement timeline and budget cycle, and equipping the physician champion with materials that extend beyond clinical talking points. The most effective approach treats hospital adoption as a commercial strategy problem requiring dedicated market access infrastructure, not simply a sales activity problem solved by adding more field representatives.
If your positioning, your campaigns, and your reporting need to work as one system, and you want someone who's built that inside healthcare before, let's talk.
Book a 20-minute discovery call